Trajan Group is an Australian-headquartered developer and manufacturer of analytical and life-sciences products used in laboratories that test everything from human health samples to food and the environment. Its fortunes are tied less to domestic construction than to the global capital-expenditure cycle for scientific instruments and consumables, particularly in North America.

With the FY26 result released in late August 2026, investors have a fresh read on whether a recovery in laboratory Capital spending could underpin the next re-rating, as the headline asks.

Latest Development

Trajan announced its FY26 full-year results on 27 August 2026. Group Revenue was A$161.4 million, down 3.1% on the prior year, and normalised EBITDA fell 14.7% to A$13.2 million. Second-half normalised EBITDA of A$8.1 million was materially stronger than the first half, and the company improved its second-half pro forma gross Margin from 37.4% to 40.6%.

Management pointed to foreign-exchange headwinds, weakness in North American capital-equipment funding and the loss of Certus-related revenue as the main drags on the year, while framing FY27 as a rebound supported by cost reductions.

What Could Drive the Shares Next?

The key swing Factor is the North American laboratory and life-sciences capital-spending environment; a genuine turn in that cycle would lift Trajan's most operationally geared revenue line. Delivery against the FY27 guidance, continued gross-margin improvement, and evidence that recurring consumables revenue is offsetting lumpier equipment sales would all support the case.

New product introductions and any bolt-on acquisitions that deepen the consumables mix are additional potential catalysts.

Risks Investors Should Watch

Trajan earns a large share of revenue offshore, so currency movements can meaningfully affect reported results. Demand for capital equipment remains dependent on research-funding conditions that are outside the company's control, and a prolonged funding squeeze would pressure the FY27 rebound.

Execution on cost reduction and the integration of past acquisitions also carry risk, and the loss of specific revenue streams such as Certus shows how contract or partner changes can move the numbers.

Investor Takeaway

Trajan's FY26 result was a softer Top Line offset by a clear second-half margin recovery and a constructive FY27 outlook. Whether the capital-expenditure cycle powers a re-rating will depend on North American funding conditions and on the company delivering the mid-single-digit revenue and double-digit EBITDA growth it has guided to. The FY27 half-year update will be the first meaningful check on that trajectory.